Study of Neoadjuvant Myocet®, Paclitaxel, Pertuzumab, and Trastuzumab in HER2-positive Breast Cancer
Status:
Completed
Trial end date:
2016-01-01
Target enrollment:
Participant gender:
Summary
This is a prospective, multicenter, single-arm, phase II study to evaluate the safety of
neoadjuvant liposomal doxorubicin plus paclitaxel, trastuzumab, and pertuzumab in patients
with HER2-positive breast cancer